Article
Public, Environmental & Occupational Health
Olga Syrkina, Ajinkya Inamdar, Sophie Wague, Celine Monfredo, Markku Nissila, Anne-Laure Chabanon, Laurence Serradell
Summary: This study conducted enhanced safety surveillance for the quadrivalent inactivated split-virion influenza vaccine (IIV4) in Finland during the 2020/21 season. The results showed no clinically significant changes in what is known or expected for IIV4, supporting the safety profile of this vaccine and maintaining public confidence in influenza vaccination.
Article
Public, Environmental & Occupational Health
Anne-Laure Chabanon, Sophie Wague, Annick Moureau, Markku Nissila, Laurence Serradell
Summary: The passive safety surveillance of a quadrivalent inactivated split-virion influenza vaccine in Finland for the 2019/20 season did not reveal any clinically significant changes in expected adverse drug reactions. The most frequently reported suspected adverse reactions within 7 days post-vaccination were site pain, site reaction, and fever, with no serious adverse reactions reported. Reported adverse reaction rates were consistent with previous assessments, indicating an overall safe profile for the vaccine.
Article
Immunology
Yaping Chen, Yanhui Xiao, Ying Ye, Feng Jiang, Hanqing He, Linyun Luo, Haiping Chen, Lubin Shi, Qiuyue Mu, Wei Chen, Xue Guo, Min Zhang, Jun Li, Qinghu Guan, Zhiping Chen, Xiaoming Yang
Summary: This study demonstrates that in infants, coadministration of an inactivated enterovirus 71 vaccine (EV71 vaccine) with trivalent split-virion inactivated influenza vaccine (IIV3) is safe and does not interfere with immunogenicity.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Medicine, General & Internal
Benjamin N. Rome, William B. Feldman, Michael A. Fischer, Rishi J. Desai, Jerry Avorn
Summary: Concurrent administration of influenza and zoster vaccines may lead to a reduction in receipt of the influenza vaccine the following year, possibly due to patients misattributing systemic side effects caused by the zoster vaccine to the influenza vaccine. It is suggested to administer these two vaccines separately or provide enhanced counseling to patients about expected vaccine side effects.
Article
Immunology
Kailey Hughes, Donald B. Middleton, Mary Patricia Nowalk, Goundappa K. Balasubramani, Emily T. Martin, Manjusha Gaglani, H. Keipp Talbot, Manish M. Patel, Jill M. Ferdinands, Richard K. Zimmerman, Fernanda P. Silveira
Summary: This study evaluated the vaccine effectiveness against influenza hospitalization among immunocompromised adults during the 2017-2018 influenza season. The results showed that while immunocompromised adults had a higher vaccination rate, their protection against influenza was lower, with a vaccine effectiveness of 33% in the overall adult population. Further research is needed to assess vaccine effectiveness among different immunocompromising conditions and explore ways to improve effectiveness for immunocompromised individuals.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Immunology
Nathaniel M. Lewis, Jessie R. Chung, Timothy M. Uyeki, Lisa Grohskopf, Jill M. Ferdinands, Manish M. Patel
Summary: This study analyzes the comparability of relative vaccine effectiveness across different studies and suggests that this comparability is dependent on the absolute vaccine effectiveness of the comparator vaccine. These findings have implications for the design of influenza vaccine studies and data reporting.
CLINICAL INFECTIOUS DISEASES
(2022)
Article
Infectious Diseases
Sonja Gandhi-Banga, Sophie Wague, Anju Shrestha, Olga Syrkina, Oxana Talanova, Markku Nissilae, Karl Stuff, Celine Monfredo
Summary: Enhanced passive safety surveillance for quadrivalent inactivated split-virion influenza vaccines in Germany and Finland during the 2021/22 influenza season did not indicate any clinically relevant changes in safety compared to what is known/expected for these vaccines. The rate of adverse drug reactions reported within 7 days post-vaccination was 1.88% in Germany and 4.90% in Finland.
INFLUENZA AND OTHER RESPIRATORY VIRUSES
(2023)
Article
Immunology
Ui Yoon Choi, Ki Hwan Kim, Kyung Yil Lee, Jong-Hyun Kim, Chun Soo Kim, Byung Wook Eun, Hwang Min Kim, Dong Ho Kim, Song Eun Song, Dae Sun Jo, Jin Lee, Sang Hyuk Ma, Kwang Nam Kim, Jin Han Kang
Summary: The study evaluated the immunogenicity and safety of a novel quadrivalent inactivated influenza vaccine, GC3110A, in Korean children aged 6-35 months, showing comparable results to the traditional trivalent vaccine TIV in terms of immunogenicity and safety.
Article
Immunology
Leora R. Feldstein, Jill M. Ferdinands, Wesley H. Self, Adrienne G. Randolph, Michael Aboodi, Adrienne H. Baughman, Samuel M. Brown, Matthew C. Exline, D. Clark Files, Kevin Gibbs, Adit A. Ginde, Michelle N. Gong, Carlos G. Grijalva, Natasha Halasa, Akram Khan, Christopher J. Lindsell, Margaret Newhams, Ithan D. Peltan, Matthew E. Prekker, Todd W. Rice, Nathan I. Shapiro, Jay Steingrub, H. Keipp Talbot, M. Elizabeth Halloran, Manish Patel
Summary: This study simulated data to estimate potential biases in influenza vaccine effectiveness when using clinical testing. The results showed that bias in testing would have to be substantial and overall proportion of patients tested would have to be small to result in a meaningful difference in vaccine effectiveness estimation.
JOURNAL OF INFECTIOUS DISEASES
(2021)
Article
Immunology
Haiping Chen, Zhuoying Huang, Shaoying Chang, Mei Hu, Qingbin Lu, Yuntao Zhang, Hui Wang, Yanhui Xiao, Yonghong Ge, Yong Zou, Fuqiang Cui, Shasha Han, Min Zhang, Shengyi Wang, Xiaoping Zhu, Biao Zhang, Zhi Li, Jia Ren, Xiao Chen, Rui Ma, Lei Zhang, Xue Guo, Linyun Luo, Xiaodong Sun, Xiaoming Yang
Summary: This study aimed to investigate the safety and immunogenicity of the coadministration of an inactivated SARS-CoV-2 vaccine, quadrivalent split-virion inactivated influenza vaccine, and 23-valent pneumococcal polysaccharide vaccine in adults in China. The results showed that the coadministration scheme is safe and comparable in immunogenicity to the individual vaccine regimens.
Article
Immunology
Emily T. Martin, Caroline Cheng, Joshua G. Petrie, Elif Alyanak, Manjusha Gaglani, Donald B. Middleton, Shekhar Ghamande, Fernanda P. Silveira, Kempapura Murthy, Richard K. Zimmerman, Arnold S. Monto, Christopher Trabue, H. Keipp Talbot, Jill M. Ferdinands
Summary: The study evaluated the vaccine effectiveness against A(H3N2) during the 2016-2017 and 2017-2018 influenza seasons, finding relatively low effectiveness against the A(H3N2) vaccine virus, especially A/Hong Kong/4801/2014. This suggests ongoing changes in H3N2 antigenic epitopes may impact the vaccine efficacy.
JOURNAL OF INFECTIOUS DISEASES
(2021)
Article
Immunology
Ivan Martinez-Baz, Miguel Fernandez-Huerta, Ana Navascues, Francisco Pozo, Camino Trobajo-Sanmartin, Itziar Casado, Aitziber Echeverria, Carmen Ezpeleta, Jesus Castilla
Summary: This study estimated the effectiveness of the influenza vaccine in preventing outpatient and hospitalized cases in the 2022-2023 season. The results showed that the vaccine was effective against influenza B, moderately effective against A(H3N2), and ineffective against A(H1N1). The effectiveness of the vaccine was lower in hospitalized patients compared to outpatients, possibly due to a lower proportion of influenza B cases. The null effectiveness against A(H1N1) was consistent with antigenic drift and supported the use of a new composition for the 2023-2024 influenza vaccine.
Article
Immunology
Jill M. Ferdinands, Manjusha Gaglani, Shekhar Ghamande, Emily T. Martin, Donald Middleton, Arnold S. Monto, Fernanda Silveira, Helen K. Talbot, Richard Zimmerman, Emily R. Smith, Manish Patel
Summary: The study estimated vaccine effectiveness for prevention of influenza-associated hospitalizations in adults during the 2018-2019 influenza season. The results showed positive effectiveness against influenza A(H1N1)pdm09 but no protection against influenza A(H3N2), with significant differences by age group noted.
JOURNAL OF INFECTIOUS DISEASES
(2021)
Article
Biotechnology & Applied Microbiology
Xiaoyuan Huang, Ting Fan, Li Li, Xuanxuan Nian, Jiayou Zhang, Xuefen Gao, Wei Zhao, Wei Chen, Zhaoqing Zhang, Zhihao Yao, Xixin Han, Jinrong Shi, Ying Wang, Haihe Bian, Nianmin Shi, Xinguo Li, Kai Duan, Guohua Li, Xiaoming Yang
Summary: This study evaluated the safety and immunogenicity of the quadrivalent split influenza vaccine IIV4-W in different age groups. The results showed that IIV4-W had a non-inferior immune response for matched strains and a superior immune response for additional B strains, and it was safe for participants.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2022)
Review
Immunology
Constantina Boikos, Ian McGovern, Deborah Molrine, Justin R. Ortiz, Joan Puig-Barbera, Mendel Haag
Summary: This study summarizes the relative vaccine effectiveness (rVE) of the cell-based quadrivalent inactivated influenza vaccine (IIV4c) versus the egg-based quadrivalent influenza vaccines (IIV4e) in preventing influenza-related medical encounters (IRMEs). The results show that IIV4c consistently has higher relative effectiveness than IIV4e, regardless of the circulating strains and antigenic drift or egg adaptation.
Article
Immunology
Camino Trobajo-Sanmartin, Ana Miqueleiz, Marcela Guevara, Miguel Fernandez-Huerta, Cristina Burgui, Itziar Casado, Fernando Baigorria, Ana Navascues, Carmen Ezpeleta, Jesus Castilla
Summary: This study compared the risk of COVID-19 outcomes among different co-circulating SARS-CoV-2 variants in Navarra, Spain. The Alpha and Delta variants were associated with a higher risk of hospitalization and severe disease, while the Omicron BA.1 and BA.2 variants showed lower risks.
JOURNAL OF INFECTIOUS DISEASES
(2023)
Article
Medicine, General & Internal
Cristina Burgui, Ramon San Miguel, Silvia Goni-Esarte, Regina Juanbeltz, Juan Isidro Uriz-Otano, Jesus Reparaz, Maite Sarobe, Jose Manuel Zozaya, Jesus Castilla
Summary: This study shows that second-generation DAAs are highly effective in treating HCV infection in real-life conditions and have the capacity to eliminate HCV infection in the general population.
POSTGRADUATE MEDICINE
(2023)
Article
Oncology
Carlota Castro-Espin, Catalina Bonet, Marta Crous-Bou, Verena Katzke, Charlotte Le Cornet, Franziska Jannasch, Matthias B. Schulze, Anja Olsen, Anne Tjonneland, Christina C. Dahm, Christian S. Antoniussen, Maria Jose Sanchez, Pilar Amiano, Maria Dolores Chirlaque, Marcela Guevara, Claudia Agnoli, Rosario Tumino, Carlotta Sacerdote, Maria Santucci De Magistris, Malin Sund, Stina Boden, Torill Enget Jensen, Karina Standahl Olsen, Guri Skeie, Marc J. Gunter, Sabina Rinaldi, Esther M. Gonzalez-Gil, Elisabete Weiderpass, Sofia Christakoudi, Alicia K. Heath, Laure Dossus, Antonio Agudo
Summary: This study aimed to investigate the relationship between pre-diagnostic dietary patterns related to inflammatory, insulin, and estrogenic pathways and breast cancer (BC) survival. The results showed that adherence to an anti-diabetic and anti-inflammatory diet was associated with lower overall mortality among BC survivors, while no significant association was found with the estrogen-related dietary pattern. Therefore, following these dietary patterns could potentially improve the prognosis of BC survivors.
BRITISH JOURNAL OF CANCER
(2023)
Article
Infectious Diseases
Ivan Martinez-Baz, Camino Trobajo-Sanmartin, Ana Miqueleiz, Itziar Casado, Ana Navascues, Cristina Burgui, Carmen Ezpeleta, Jesus Castilla, Marcela Guevara
Summary: During the Omicron BA.1-predominant period, full COVID-19 vaccination greatly reduced the risk of hospitalisation and severe outcomes in COVID-19 cases, and a booster dose further improved this effect, particularly in individuals aged over 65 years.
Article
Infectious Diseases
Esther Kissling, Francisco Pozo, Ivan Martinez-Baz, Silke Buda, Ana-Maria Vilcu, Lisa Domegan, Clara Mazagatos, Frederika Dijkstra, Neus Latorre-Margalef, Sanja Kurecic Filipovic, Ausenda Machado, Mihaela Lazar, Itziar Casado, Ralf Duerrwald, Sylvie van der Werf, Joan O'Donnell, Juan Antonio Linares Dopido, Adam Meijer, Maximilian Riess, Vesna Visekruna Vucina, Ana Paula Rodrigues, Maria Elena Mihai, Jesus Castilla, Luise Goerlitz, Alessandra Falchi, Jeff Connell, Daniel Castrillejo, Mariette Hooiveld, Annasara Carnahan, Maja Ilic, Raquel Guiomar, Alina Ivanciuc, Marine Maurel, Ajibola Omokanye, Marta Valenciano, Ivan Mlinaric, Bernard Kaic, Ivana Ferencak, Katica Cusek Adamic, Mirjana Lana Kosanovic Licina, Danijela Lakoseljac, Ivana Mihin Huskic, Diana Nonkovic, Thierry Blanchon, Caroline Guerrisi, Titouan Launay, Hayat Benamar, Julie Sevila, Shirley Masse, Sylvie Behillil, Vincent Enouf, Ute Preuss, Kirstin Tolksdorf, Marianne Wedde, Barbara Biere, Adele Mckenna, Charlene Bennett, Joanne Moran, Grainne Tuite, Cillian de Gascun, Michael Joyce, Olga Levis, Claire Collins, Cristina Burgui, Ana Navascues, Ana Miqueleiz, Carmen Ezpeleta, Marit de Lange, Mariam Bagheri, Sharon van den Brink, Sacha van Deemter, Gabriel Goderski, Chantal Herrebrugh, Liz Jenniskens, Wesley Jones, John Sluimer, Daphne Reukers, Tara Sprong, Anne Teirlinck, Eddie Vierklau, Lisa Wijsman, Rianne van Gageldonk-Lafeber, Veronica Gomez, Irina Kislaya, Nuno Verdasca, Ines Costa, Aryse Melo, Olivia Timnea, Adrian Jidovu, Catalina Pascu, Sorin Dinu, Iulia Bistriceanu, Mihaela Oprea, Rodica Popescu, Amparo Larrauri, Concepcion Delgado-Sanz, Inmaculada Casas, Ana Martinez Mateo, Luca Basile, Carmen Quinones Rubio, Eva Martinez Ochoa, Virtudes Gallardo, Nicola Lorusso, Cecilia Gordillo Romero, Asa Wiman, Lena Dillner, Elin Arvesen, Nora Nid, Wissam Alhindi, Tove Samuelsson Hagey
Summary: In the 2021-2022 influenza season, influenza A viruses were dominant in Europe. A multicentre test-negative study conducted by the I-MOVE primary care network showed that the overall vaccine effectiveness against A(H1N1)pdm09 was 75% and against A(H3N2) was 29%. The highest vaccine effectiveness was observed among individuals aged 15-64 years for both influenza A subtypes. The study also found that despite antigenic mismatch, the vaccine was still able to provide protection against laboratory-confirmed influenza among those vaccinated.
INFLUENZA AND OTHER RESPIRATORY VIRUSES
(2023)
Article
Medicine, General & Internal
J. Castilla, M. Garcia Cenoz, R. Abad, L. Sanchez-Cambronero, N. Lorusso, C. Izquierdo, S. Canellas Llabres, J. Roig, A. Malvar, F. Gonzalez Carril, A. L. D. Boone, J. Perez Martin, M. J. Rodriguez Recio, A. Galmes, A. Caballero, A. Garcia Rojas, F. Juanas, M. Nieto, L. J. Viloria Raymundo, E. Martinez Ochoa, A. Rivas, D. Castrillejo, D. Moreno Perez, A. Martinez, E. Borras, A. Sanchez Gomez, E. Pastor, V Nartallo, J. M. Arteagoitia, B. Alvarez-Fernandez, R. Garcia Pina, S. Fernandez Arribas, J. Vanrell, S. Garcia Hernandez, R. M. Mendoza, M. Mendez, M. M. Lopez-Tercero, A. Fernandez-Rodriguez, A. Blanco, F. J. Carrillo de Albornoz, J. Ruiz Olivares, R. Ruiz-Montero, A. Limia, J. A. Navarro-Alonso, J. A. Vazquez, A. Barricarte
Summary: This study assessed the effectiveness of a protein-based meningococcal vaccine in preventing invasive meningococcal disease in Spanish children. The results showed that complete vaccination with the vaccine was 76% effective against invasive meningococcal disease caused by any serogroup, and partial vaccination was 54% effective.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Immunology
Teresa del Rosal, M. Luz Garcia-Garcia, Inmaculada Casas, Maria Iglesias-Caballero, Francisco Pozo, Sonia Alcolea, Blanca Bravo, Jose M. Rodrigo-Munoz, Victoria del Pozo, Cristina Calvo
Summary: The prevalence of TTV infection in children with respiratory infections was evaluated in this study, and its correlations with outcomes and immune response were analyzed. The results showed that TTV infection is common in children with respiratory infections and is associated with abnormal chest radiograph, disease severity, and changes in protein expression and release.
PEDIATRIC INFECTIOUS DISEASE JOURNAL
(2023)
Article
Oncology
Sofia Christakoudi, Konstantinos K. Tsilidis, Laure Dossus, Sabina Rinaldi, Elisabete Weiderpass, Christian S. Antoniussen, Christina C. Dahm, Anne Tjonneland, Lene Mellemkjaer, Verena Katzke, Rudolf Kaaks, Matthias B. Schulze, Giovanna Masala, Sara Grioni, Salvatore Panico, Rosario Tumino, Carlotta Sacerdote, Anne M. May, Evelyn M. Monninkhof, J. Ramon Quiros, Catalina Bonet, Maria-Jose Sanchez, Pilar Amiano, Maria-Dolores Chirlaque, Marcela Guevara, Ann H. Rosendahl, Tanja Stocks, Aurora Perez-Cornago, Sandar Tin Tin, Alicia K. Heath, Elom K. Aglago, Laia Peruchet-Noray, Heinz Freisling, Elio Riboli
Summary: Associations between body shape and breast cancer risk remain unclear. Although waist and hip circumferences are strongly positively correlated with body mass index (BMI), waist-to-hip ratio is still associated with breast cancer risk, especially in post-menopausal women, those aged >= 55 years, and ER- and PR- subtypes.
Article
Oncology
Anna Palomar-Cros, Kurt Straif, Dora Romaguera, Nuria Aragones, Gemma Castano-Vinyals, Vicente Martin, Victor Moreno, Ines Gomez-Acebo, Marcela Guevara, Amaia Aizpurua, Ana Molina-Barcelo, Jose-Juan Jimenez-Moleon, Adonina Tardon, Manuel Contreras-Llanes, Rafael Marcos-Gragera, Jose M. Huerta, Beatriz Perez-Gomez, Ana Espinosa, Natalia Hernandez-Segura, Mireia Obon-Santacana, Jessica Alonso-Molero, Rosana Burgui, Pilar Amiano, Marina Pinto-Carbo, Rocio Olmedo-Requena, Guillermo Fernandez-Tardon, Vanessa Santos-Sanchez, Nerea Fernandez de Larrea-Baz, Tania Fernandez-Villa, Delphine Casabonne, Trinidad Dierssen-Sotos, Eva Ardanaz, Ane Dorronsoro, Marina Pollan, Manolis Kogevinas, Camille Lassale
Summary: The use of artificial sweeteners such as aspartame, cyclamate, saccharin and sucralose is widespread, but there is no significant association between their consumption and cancer risk in the general population. However, high consumption of other artificial sweeteners may be linked to an increased risk of colorectal and stomach cancer in individuals with diabetes.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Microbiology
Blanca Bravo-Queipo-de-Llano, Laura Sanchez Garcia, Inmaculada Casas, Francisco Pozo, Leticia La Banda, Sonia Alcolea, Jorge Atucha, Rocio Sanchez-Leon, Adelina Pellicer, Cristina Calvo
Summary: This study reports on viral respiratory infections (VRIs) in very low birthweight infants during NICU admission and compares data collected before and after the COVID-19 pandemic. The results showed a significant decrease in the incidence of VRI during the pandemic, possibly due to increased infection prevention measures globally.
Article
Immunology
Yujia Zhao, Douglas I. Walker, Christina M. Lill, Bastiaan R. Bloem, Sirwan K. L. Darweesh, Brismar Pinto-Pacheco, Brooklyn McNeil, Gary W. Miller, Alicia K. Heath, Myrthe Frissen, Dafina Petrova, Maria-Jose Sanchez, Maria-Dolores Chirlaque, Marcela Guevara, Maurizio Zibetti, Salvatore Panico, Lefkos Middleton, Verena Katzke, Rudolf Kaaks, Elio Riboli, Giovanna Masala, Sabina Sieri, Raul Zamora-Ros, Pilar Amiano, Mazda Jenab, Susan Peters, Roel Vermeulen
Summary: This study investigated the association between blood levels of LBP and the risk of Parkinson's disease (PD) in a large European prospective cohort. The results showed that higher plasma LBP levels were associated with an increased risk of PD, especially among women and overweight/obese individuals.
JOURNAL OF NEUROINFLAMMATION
(2023)
Article
Immunology
Ivan Martinez-Baz, Miguel Fernandez-Huerta, Ana Navascues, Francisco Pozo, Camino Trobajo-Sanmartin, Itziar Casado, Aitziber Echeverria, Carmen Ezpeleta, Jesus Castilla
Summary: This study estimated the effectiveness of the influenza vaccine in preventing outpatient and hospitalized cases in the 2022-2023 season. The results showed that the vaccine was effective against influenza B, moderately effective against A(H3N2), and ineffective against A(H1N1). The effectiveness of the vaccine was lower in hospitalized patients compared to outpatients, possibly due to a lower proportion of influenza B cases. The null effectiveness against A(H1N1) was consistent with antigenic drift and supported the use of a new composition for the 2023-2024 influenza vaccine.
